There are no approved pharmacologic therapies for chronic sensorineural hearing loss (SNHL). The combination of CHIR99021+valproic acid (CV, FX-322) has been shown to regenerate mammalian cochlear hair cells ex vivo. The objectives were to ...

February 15, 2023 - Frequency Therapeutics halted its clinical trial for the experimental hearing loss drug FX-322 due to disappointing clinical trials results.

February 13, 2023 - Frequency Therapeutics, Inc. (Nasdaq: FREQ), a regenerative medicine company focused on developing therapeutics to activate a person’s innate potential to restore function, today announced clinical results from the placebo-controlled Phase 2b study of FX-322 in individuals with acquired…

January 11, 2024 - FX 322 is a small molecule drug, being developed by Frequency Therapeutics, for the treatment of sensorineural hearing loss (SNHL). FX 322 has been formulated

Delivery of FX-322 to the extended high-frequency region of the cochlea is well tolerated and enhances speech recognition performance in multiple subjects with stable chronic hearing loss.

August 13, 2024 - At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

April 21, 2023 - This is a Phase 2, prospective, randomized, double-blind, placebo-controlled, single-dose, multicenter study to evaluate the efficacy of FX-322, administered by intratympanic injection, in adults with acquired sensorineural hearing loss (SNHL).

April 10, 2019 - Frequency Therapeutics has reported positive data from a Phase I/II clinical trial of investigational drug FX-322 intended for hearing restoration.

October 12, 2022 - Frequency Therapeutics, Inc. today announced that it has completed enrollment of its placebo-controlled Phase 2b study of FX-322 in adults with acquired sensorineural hearing loss (SNHL).

February 13, 2023 - Frequency Therapeutics shares were down more than 80% after the company announced the failure of the Phase 2b study for FX-322.

April 27, 2023 - This is a phase 2a single and repeat dose exploratory efficacy study of intratympanic FX-322 compared to placebo in healthy male and female adults with stable sensorineural hearing loss.

August 14, 2023 - Just last month, Korro Bio agreed to combine with Frequency Therapeutics through a reverse merger set to close in the fourth quarter. Frequency’s former lead candidate FX-322 in February failed a Phase IIb trial (FX-322-208; NCT05086276) in patients with acquired sensorineural hearing loss.

December 9, 2021 - Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage regenerative medicine company focused on developing therapeutics to activate a person’s

June 8, 2022 - (518) 701-2085 | Can a single dose medication potentially restore lost hearing? We’re working to find out. The physicians of Albany ENT and Allergy Services are helping to lead the charge and conducting clinical studies regarding FX-322, a new investigational drug that aims to activate and ...

April 18, 2023 - FX-322 is a new pharmaceutical research drug by Frequency Therapeutics aimed at finding a cure for hearing loss. This article will discuss updates in the drug’s development and its effectiveness in…

July 17, 2019 - Astellas Obtains the Exclusive Rights to Develop and Commercialize FX-322 in Ex-US Markets; Frequency Retains U.S. Rights Frequency will Receive $80 Million Upfront from Astellas with the Potential of up to $545 Million in Future Milestone Payments as well as Double-Digit Royalties

February 24, 2021 - Frequency Therapeutics, Inc (Nasdaq: FREQ) announced the publication of its FX-322 Phase 1/2 study results in Otology & Neurotology.

Study record managers: refer to the Data Element Definitions if submitting registration or results information